Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06654700 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).

StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Completed without a posted recruiting period Show 5 more changesShow less
    • Primary and study completion dates changed from estimate of May 1, 2025 to May 9, 2025
    • Start date changed from estimate of Dec 9, 2024 to Dec 16, 2024
    • Eligibility criteria expanded, about 25 words
    • Secondary endpoints: details revised at 5 of 6 entries
    • Site contact updated
  2. Start date: Nov 1, 2024 to Dec 9, 2024v3
  3. Primary endpoint revised
    • Secondary endpoints revised (6)
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the lot-to lot consistency of three batches of recombinant herpes zoster vaccine (CHO cell) produced on a commercial scale in subjects aged 40 years and older after receiving 2 doses on a 0, 2 month schedule.
Trial Details
NCT Number NCT06654700
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Conditions
(from sponsor)		 Herpes Zoster
Related terms Herpes Zoster
Enrollment 1,200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov